Astrocyte-mediated purinergic signaling is upregulated in a mouse model of Fragile X syndrome
- PMID: 33754385
- DOI: 10.1002/glia.23997
Astrocyte-mediated purinergic signaling is upregulated in a mouse model of Fragile X syndrome
Abstract
Fragile X syndrome (FXS) is the leading monogenic cause of intellectual disability and autism spectrum disorders. With increasing investigation into the molecular mechanisms underlying FXS, there is growing evidence that perturbations in glial signaling are widely associated with neurological pathology. Purinergic signaling, which utilizes nucleoside triphosphates as signaling molecules, provides one of the most ubiquitous signaling systems for glial-neuronal and glial-glial crosstalk. Here, we sought to identify whether purinergic signaling is dysregulated within the FXS mouse cortex, and whether this dysregulation contributes to aberrant intercellular communication. In primary astrocyte cultures derived from the Fmr1 knockout (KO) mouse model of FXS, we found that application of exogenous ATP and UTP evoked elevated intracellular calcium responses compared to wildtype levels. Accordingly, purinergic P2Y2 and P2Y6 receptor expression was increased in Fmr1 KO astrocytes both in vitro and in acutely dissociated tissue, while P2Y antagonism via suramin prevented intracellular calcium elevations, suggesting a role for these receptors in aberrant FXS astrocyte activation. To investigate the impact of elevated purinergic signaling on astrocyte-mediated synaptogenesis, we quantified synaptogenic protein TSP-1, known to be regulated by P2Y activation. TSP-1 secretion and expression were both heightened in Fmr1 KO vs wildtype astrocytes following UTP application, while naïve TSP-1 cortical expression was also transiently elevated in vivo, indicating increased potential for excitatory TSP-1-mediated synaptogenesis in the FXS cortex. Together, our results demonstrate novel and significant purinergic signaling elevations in Fmr1 KO astrocytes, which may serve as a potential therapeutic target to mitigate the signaling aberrations observed in FXS.
Keywords: ATP; Fragile X syndrome; P2Y; UTP; astrocyte; cortex; purinergic signaling; thrombospondin-1.
© 2021 Wiley Periodicals LLC.
Similar articles
-
Dysregulated Purinergic Signalling in Fragile X Syndrome Cortical Astrocytes.Neuromolecular Med. 2024 Sep 10;26(1):36. doi: 10.1007/s12017-024-08802-4. Neuromolecular Med. 2024. PMID: 39254908
-
Purinergic Signalling Mediates Aberrant Excitability of Developing Neuronal Circuits in the Fmr1 Knockout Mouse Model.Mol Neurobiol. 2024 Nov;61(11):9507-9528. doi: 10.1007/s12035-024-04181-w. Epub 2024 Apr 23. Mol Neurobiol. 2024. PMID: 38652351
-
Selective Deletion of Astroglial FMRP Dysregulates Glutamate Transporter GLT1 and Contributes to Fragile X Syndrome Phenotypes In Vivo.J Neurosci. 2016 Jul 6;36(27):7079-94. doi: 10.1523/JNEUROSCI.1069-16.2016. J Neurosci. 2016. PMID: 27383586 Free PMC article.
-
BDNF in fragile X syndrome.Neuropharmacology. 2014 Jan;76 Pt C:729-36. doi: 10.1016/j.neuropharm.2013.05.018. Epub 2013 May 29. Neuropharmacology. 2014. PMID: 23727436 Review.
-
Aberrant mitochondrial bioenergetics in the cerebral cortex of the Fmr1 knockout mouse model of fragile X syndrome.Biol Chem. 2020 Mar 26;401(4):497-503. doi: 10.1515/hsz-2019-0221. Biol Chem. 2020. PMID: 31702995 Review.
Cited by
-
Dysregulated cholesterol metabolism, aberrant excitability and altered cell cycle of astrocytes in fragile X syndrome.Glia. 2023 May;71(5):1176-1196. doi: 10.1002/glia.24331. Epub 2023 Jan 3. Glia. 2023. PMID: 36594399 Free PMC article.
-
Dysregulated Purinergic Signalling in Fragile X Syndrome Cortical Astrocytes.Neuromolecular Med. 2024 Sep 10;26(1):36. doi: 10.1007/s12017-024-08802-4. Neuromolecular Med. 2024. PMID: 39254908
-
Modification of Neural Circuit Functions by Microglial P2Y6 Receptors in Health and Neurodegeneration.Mol Neurobiol. 2025 Apr;62(4):4139-4148. doi: 10.1007/s12035-024-04531-8. Epub 2024 Oct 14. Mol Neurobiol. 2025. PMID: 39400857 Free PMC article. Review.
-
Understanding autism spectrum disorders with animal models: applications, insights, and perspectives.Zool Res. 2021 Nov 18;42(6):800-824. doi: 10.24272/j.issn.2095-8137.2021.251. Zool Res. 2021. PMID: 34755500 Free PMC article. Review.
-
Activity of Human-Specific Interlaminar Astrocytes in a Chimeric Mouse Model of Fragile X Syndrome.Int J Mol Sci. 2025 Jul 6;26(13):6510. doi: 10.3390/ijms26136510. Int J Mol Sci. 2025. PMID: 40650286 Free PMC article.
References
REFERENCES
-
- Abbracchio, M. P., Burnstock, G., Verkhratsky, A., & Zimmermann, H. (2009). Purinergic signalling in the nervous system: An overview. Trends in Neurosciences, 32(1), 19-29. https://doi.org/10.1016/j.tins.2008.10.001
-
- Adams, J. B., Audhya, T., McDonough-Means, S., Rubin, R. A., Quig, D., Geis, E., … Lee, W. (2011). Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity. Nutrition & Metabolism (London), 8(1), 34. https://doi.org/10.1186/1743-7075-8-34
-
- Alves, M., Gomez-Villafuertes, R., Delanty, N., Farrell, M. A., O'Brien, D. F., Miras-Portugal, M. T., … Engel, T. (2017). Expression and function of the metabotropic purinergic P2Y receptor family in experimental seizure models and patients with drug-refractory epilepsy. Epilepsia, 58(9), 1603-1614. https://doi.org/10.1111/epi.13850
-
- Apolloni, S., Finocchi, P., D'Agnano, I., Alloisio, S., Nobile, M., D'Ambrosi, N., & Volonte, C. (2010). UDP exerts cytostatic and cytotoxic actions in human neuroblastoma SH-SY5Y cells over-expressing P2Y6 receptor. Neurochemistry International, 56(5), 670-678. https://doi.org/10.1016/j.neuint.2010.02.003
-
- Arlt, W., Reincke, M., Siekmann, L., Winkelmann, W., & Allolio, B. (1994). Suramin in adrenocortical cancer: Limited efficacy and serious toxicity. Clinical Endocrinology, 41, 299-307.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous